# Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT01062399** · PHASE1,PHASE2 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 279 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** concurrent RAD001 10 mg/day
- **DRUG:** concurrent temozolomide
- **RADIATION:** Radiation therapy
- **DRUG:** concurrent RAD001 2.5 mg/day
- **DRUG:** concurrent RAD001 5 mg/day
- **DRUG:** post-radiation RAD001 10 mg/day
- **DRUG:** post-radiation temozolomide

## Key facts

- **NCT ID:** NCT01062399
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2016-06
- **Final completion:** 2022-05-20
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2022-06-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01062399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01062399, "Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01062399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*